Enable AccessibilityEnable Accessibility

Soren Tulstrup To Lead Shire HGT's MPS Franchise

July 30, 2012

Shire plc (LSE: SHP, NASDAQ: SHPGY), today announced the appointment of Soren Tulstrup as Senior Vice President and Franchise Lead, MPS (mucopolysaccharides) for its Human Genetic Therapies (HGT) business. In this role, Soren will be responsible for developing global strategy for the MPS franchise, which includes both commercial and pipeline products, and will play a key role in strategic decisions made about the Company’s growing rare disease portfolio. He will report to Sylvie Grégoire, President of Shire HGT, and will be based in Shire’s office in Nyon, Switzerland.

“Shire HGT is well positioned for continued sustained growth, with a strong portfolio of therapies for patients suffering from rare genetic diseases and a pipeline with significant potential. We believe Soren’s extensive global experience will be invaluable in maximizing the full potential of the MPS Franchise as we provide therapies to patients with rare conditions that enable them to lead better lives,” said Sylvie Grégoire, President, Shire HGT.

Soren is the former President and CEO of Santaris Pharma, where he led business development efforts resulting in four major partnership agreements, including an ongoing collaboration with Shire. Before joining Santaris Pharma, Soren spent over a decade at Merck & Co, both in Europe and the US, in roles of increasing responsibility. While at Merck & Co, he spearheaded the global roll-out of a key diabetes product from Phase III to launch and he was part of a team that led integration of Merck’s US based Human Health commercial operations into the Global Human Health organization. Soren has also held sales and marketing positions at Sandoz and Abbott Laboratories in a career that spans more than 20 years in the pharmaceutical industry.

Currently Vice Chairman of European Biopharmaceutical Enterprises and a former Board Director of miRagen Therapeutics, he speaks six languages including Danish, English, French, German, Swedish and Norwegian.  Soren has a Bachelor of Business Administration in International Business and Modern Languages and a Master of Science in Economics and Business Administration at the Copenhagen Business School.


For further information please contact:

Jessica Mann [email protected] +44 1256 894 280
Jessica Cotrone [email protected] +1 781 482 9538


Notes to editors


Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit hyperactivity disorder, human genetic therapies, gastrointestinal diseases and regenerative medicine as well as opportunities in other therapeutic areas to the extent they arise through acquisitions.  Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights.  Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company’s website: www.shire.com.



Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company’s results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of the Company’s Specialty Pharmaceuticals, Human Genetic Therapies and Regenerative Medicine products, as well as the ability to secure new products for commercialization and/or development; government regulation of the Company’s products; the Company’s ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on the Company’s products; the Company’s ability to register, maintain and enforce patents and other intellectual property rights relating to its products; the Company’s ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and uncertainties detailed from time to time in the Company’s filings with the Securities and Exchange Commission.